ARTICLE | Translation in Brief

ADAM and Ephrin

Researchers target ADAM10 in lung fibrosis

December 8, 2017 1:04 AM UTC

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by the receptor tyrosine kinase ephrin B2.

ADAM metallopeptidase domain 10 (ADAM10) is a “sheddase,” whose role is to cleave membrane proteins and release soluble ectodomains that regulate a range of cellular functions. Although it has been primarily explored for cancer, this report is the first to invoke a role for it in IPF...